T cell anergy and costimulation

Immunological Reviews

Volumn 192, Issue , 2003, Pages 161-180

  Appleman, Leonard J ^a   Boussiotis, Vassiliki A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; B7 ANTIGEN; CALCIUM; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; RAP PROTEIN; RAS PROTEIN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; CALCIUM SIGNALING; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; CELL STIMULATION; CLONAL ANERGY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION; TUMOR IMMUNOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, DIFFERENTIATION; CELL ADHESION; CLONAL ANERGY; GTP PHOSPHOHYDROLASES; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0037902480     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00009.x     Document Type: Review

References (221)

1. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000;13:829-840.
2. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970;169:1042-1049.
3. Stockinger B. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv Immunol 1999;71:229-265.
4. Kyewski B, Derbinski J, Gotter J, Klein L. Promiscuous gene expression and central T-cell tolerance: more than meets the eye. Trends Immunol 2002;23:364-371.
5. Baumann S, Krueger A, Kirchhoff S, Krammer PH. Regulation of T cell apoptosis during the immune response. Curr Mol Med 2002;2:257-272.
6. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002;80:131-137.
7. Douek DC, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-695.
8. Jamieson BD, et al. Generation of functional thymocytes in the human adult. Immunity 1999;10:569-575.
9. Nossal GJ, Pike BL. Clonal anergy: persistence in tolerant mice of antigen-binding B lymphocytes incapable of responding to antigen or mitogen. Proc Natl Acad Sci USA 1980;77:1602-1606.
10. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983;157:1434-1447.
11. Lafferty KJ, Woolnough J. The origin and mechanism of the allograft reaction. Immunol Rev 1977;35:231-262.
12. Chow CW, Davis RJ. Integration of calcium and cyclic AMP signaling pathways by 14-3-3. Mol Cell Biol 2000;20:702-712.
13. Lafferty KJ, Warren HS, Woolnough JA, Talmage DW. Immunological induction of T lymphocytes: role of antigen and the lymphocyte costimulator. Blood Cells 1978;4:395-406.
14. Quill H, Schwartz RH. Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J Immunol 1987;138:3704-3712.
15. Jenkins MK, Schwartz RH. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 1987;165:302-319.
16. Jenkins MK, Ashwell JD, Schwartz RH. Allogeneic non-T spleen cells restore the responsiveness of normal T cell clones stimulated with antigen and chemically modified antigen-presenting cells. J Immunol 1988;140:3324-3330.
17. Mueller DL, Jenkins MK, Schwartz RH. An accessory cell-derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness. J Immunol 1989;142:2617-2628.
18. Powell JD, Ragheb JA, Kitagawa-Sakakida S, Schwartz RH. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol Rev 1998;165:287-300.
19. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 1992;4:661-671.
20. Thompson CB, et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989;86:1333-1337.
21. Lindstein T, June CH, Ledbetter JA, Stella G, Thompson CB. Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989;244:339-343.
22. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal revolved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147:2461-2466.
23. Gimmi CD, et al. B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete IL-2. Proc Natl Acad Sci USA 1991;88:6575.
24. Linsley PS, Brady W, Grosmaire L, Aruffo A, Dalme NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721.
25. Freeman GJ, et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-911.
26. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-126.
27. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-609.
28. Miller JF, Morahan G, Allison J. Extrathymic acquisition of tolerance by T lymphocytes. Cold Spring Harbor Symp Quant Biol 1989;54 (Part 2):807-813.
29. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135.
30. Bachmann MF, Barner M, Kopf M. CD2 sets quantitative thresholds in T cell activation. J Exp Med 1999;190:1383-1392.
31. Boniface JJ, et al. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands [corrected]. Immunity 1998;9:459-466.
32. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994;76:287-299.
33. Rabinowitz JD, et al. Altered T cell receptor ligands trigger a subset of early T cell signals. Immunity 1996;5:125-135.
34. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and rote in T cell biology. Annu Rev Immunol 1996;14:1-27.
35. Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993;363:156-159.
36. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a tong-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 1996;184:19-29.
37. Bacchetta R, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med 1994;179:493-502.
38. de Waal Malefyt R, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915-924.
39. Groux H, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-739.
40. Kawabe Y, Ochi A. Selective anergy of V beta 8+, CD4+ T cells in Staphylococcus enterotoxm B-primed mice. J Exp Med 1990;172:1065-1070.
41. Kawabe Y, Ochi A. Programmed cell death and extrathymic reduction of Vbeta8+ CD4+ T cells in mice tolerant to Staphylococcus aureus enterotoxin B. Nature 1991;349:245-248.
42. Rellahan BL, Jones LA, Kruisbeek AM, Fry AM, Matis LA. In vivo induction of anergy in peripheral V beta 8+ T cells by staphylococcal enterotoxin B. J Exp Med 1990;172:1091-1100.
43. MacDonald HR, Baschieri S, Lees RK. Clonal expansion precedes anergy and death of V beta 8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur J Immunol 1991;21:1963-1966.
44. Green JM, et al. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994;1:501-508.
45. Shahinian A, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993;261:609.
46. Lucas PJ, Negishi I, Nakayama K, Fields LE, Loh DY. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J Immunol 1995;154:5757-5768.
47. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569.
48. Walunas TL, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.
49. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-2550.
50. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736.
51. McCoy K, Camberis M, Gros GL. Protective immunity to nematode infection is induced by CTLA-4 blockade. J Exp Med 1997;186:183-187.
52. Waterhouse P, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270:985-988.
53. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-547.
54. Bachmann MF, Kohler G, Ecabert B, Mak TW, Kopf M. Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous. J Immunol 1999;163:1128-1131.
55. Greenwald RJ, Boussiotis VA, Lorsbach RB, Abbas AK, Sharpe AH. CTLA-4 regulates induction of anergy in vivo. Immunity 2001;14:145-155.
56. Boussiotis VA, et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000;105:1317-1325.
57. Plebanski M, et al. Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum. Immunity 1999;10:651-660.
58. Pohl-Koppe A, Logigian EL, Steere AC, Hafler DA. Cross-reactivity of Borrelia burgdorferi and myelin basic protein-specific T cells is not observed in borrelial encephalomyelitis. Cell Immunol 1999;194:118-123.
59. Gross L. Intradermal immunization of C3H mice against a sarcoma that originated in an animal of the same line. Cancer Res 1943;3:326.
60. Prehn R, Main J. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 1957;18:769.
61. Klein G, Sjogren H, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res 1960;20:1561.
62. Hellstrom KE, Hellstrom I. Cellular immunity against tumor antigens. Adv Cancer Res 1968;12:167.
63. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-1798.
64. Radoja S, Saio M, Schaer D, Koneru M, Vukmanovic S, Frey AB. CDS(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J Immunol 2001;167:5042-5051.
65. fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity. J Exp Med 1995;182:1029-1036.
66. Levey DL, Srivastava PK. Alterations in T cells of cancer-bearers: whence specificity? Immunol Today 1996;17:365-368.
67. Staveley-O'Carroll K, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 1998;95:1178-1183.
68. Radoja S, Rao T, Hillman D, Frey A. Mice bearing late-stage tumors have normal functional systemic T cells responses in vitro and in vivo. J Immunol 2000;164:2619-2628.
69. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 1999;162:2227-2234.
70. Lee PP, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-685.
71. Sun H, et al. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation 1997;64:1838-1843.
72. Kirk AD, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997;94:8789-8794.
73. Larsen CP, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996;381:434-438.
74. Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 1994;83:3815-3825.
75. Blazar BR, et al. Blockade of CD40 ligand-CD40 interaction impairs CD4+ T cell-mediated alloreactivity by inhibiting mature donor T cell expansion and function after bone marrow transplantation. J Immunol 1997;158:29-39.
76. kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes. Nat Med 2000;6:290-297.
77. Guinan EC, et al. Transplantation of anergic histoincompatible bone marrow allografts. New Engl J Med 1999;340:1704-1714.
78. Samelson LE, Harford JB, Klausner RD. Identification of the components of the murine T cell antigen receptor complex. Cell 1985;43:223-231.
79. Weissman AM, Samelson LE, Klausner RD. A new subunit of the human T-cell antigen receptor complex. Nature 1986;324:480-482.
80. Samelson LE, Patel MD, Weissman AM, Harford JB, Klausner RD. Antigen activation of murine T cells induces tyrosine phosphorylation of a polypeptide associated with the T cell antigen receptor. Cell 1986;46:1083-1090.
81. Wange RL, Kong AN, Samelson LE. A tyrosine-phosphorylated 70-kDa protein hinds a photoaffinity analogue of ATP and associates with both the zeta chain and CD3 components of the activated T cell antigen receptor. J Biol Chem 1992;267:11685-11688.
82. Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992;71:649-662.
83. Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 1998;92:83-92.
84. Samelson LE. Signal transduction mediated by the T cell antigen receptor: the role of adapter proteins. Annu Rev Immunol 2002;20:371-394.
85. Sloan-Lancaster J, Shaw AS, Rothbard JB, Allen PM. Partial T cell signaling: altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy. Cell 1994;79:913-922.
86. Madrenas J, Wange RL, Wang JL, Isakov N, Samelson LE, Germain RN. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists. Science 1995;267:515-518.
87. Migita K, et al. Defective TCR-mediated signaling in anergic T cells. J Immunol 1995;155:5083-5087.
88. Gajewski TF, Qian D, Fields P, Fitch FW. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci USA 1994;91:38-42.
89. Gajewski TF, Fields P, Fitch FW. Induction of the increased Fyn kinase activity in anergic T helper type 1 clones requires calcium and protein synthesis and is sensitive to cyclosporin A. Eur J Immunol 1995;25:1836-1842.
90. Kimura M, et al. Impaired Ca/calcineurin pathway in in vivo anergized CD4 T cells. Int Immunol 2000;12:817-824.
91. Boussiotis VA, Barber DL, Lee BJ, Gribben JG, Freeman GJ, Nadler LM. Differential association of protein tyrosine kinases with the T cell receptor is linked to the induction of anergy and its prevention by B7 family-mediated costimulation. J Exp Med 1996;184:365-376.
92. Hara T, Fu SM, Hansen JA. Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J Exp Med 1985;161:1513-1524.
93. Imboden JB, Stobo JD. Transmembrane signalling by the T cell antigen receptor. Perturbation of the T3-antigen receptor complex generates inositol phosphates and releases calcium ions from intracellular stores. J Exp Med 1985;161:446-456.
94. Prasad KV, et al. T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. Proc Natl Acad Sci USA 1994;91:2834-2838.
95. Pages F, et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994;369:327-329.
96. Pagès F, et al. Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphatidylinositol 3-kinase association. J Biol Chem 1996;271:9403-9409.
97. Ward SG, Westwick J, Hall ND, Sansom DM. Ligation of CD28 receptor by B7 reduces formation of D-3 phosphoinositides in T lymphocytes independently of T cell receptor/CD3 activation. Eur J Immunol 1993;23:2572-2577.
98. August A, Dupont B. CD28 oft lymphocytes associates with phosphatidylinositol 3-kinase. Int Immunol 1994;6:769-774.
99. Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation. Proc Natl Acad Sci USA 1995;92:8891-8895.
100. August A, Sadra A, Dupont B, Hanafusa H. Src-induced activation of inducible T cell kinase (ITK) requires phosphatidylinositol 3-kinase activity and the Pleckstrin homology domain of inducible T cell kinase. Proc Natl Acad Sci USA 1997;94:11227-11232.
101. ras in CD28 signal transduction: triggering of CD28 with antibodies, but not the ligand B7-1, activates p21ras. J Exp Med 1994;180:1067-1076.
102. Stein PH, Fraser JD, Weiss A. The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3′-kinase. Mol Cell Biol 1994;14:3392-3402.
103. ras. Eur J Irranunol 1995;25:1044-1050.
104. Wang J, Auger KR, Jarvis L, Shi Y, Roberts TM. Direct association of Grb2 with the p85 subunit of phosphatidylinositol 3-kinase. J Biol Chem 1995;270:12774-12780.
105. Chuang E, et al. The CD28 and CTLA-4 receptors associate with the serine/ threonine phosphatase PP2A. Immunity 2000;13:313-322.
106. Parry RV, Olive D, Westwick J, Sansom DM, Ward SG. Evidence that a kinase distinct from protein kinase C and phosphatidylinositol 3-kinase mediates ligation-dependent serine/threonine phosphorylation of the T-lymphocyte co-stimulatory molecule CD28. Biochem J 1997;326:249-257.
107. Brunner MC, Chambers CA, Chan FK, Hanke J, Winoto A, Allison JP. CTLA-4-mediated inhibition of early events of Tcell proliferation. J Immunol 1999;162:5813-5820.
108. Greenwald RJ, et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur J Immunol 2002;32:366-373.
109. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) hind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1:793-801.
110. van der Merwe PA, Bodian DL, Daenke S, Linsley P, Davis SJ. CD80 (B7-1) binds both CD28 and CTLA-4 with a tow affinity and very fast kinetics. J Exp Med 1997;185:393-403.
111. Tivot EA, et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J Immunol 1997;158:5091-5094.
112. Masteller EL, Chuang E, Mullen AC, Reiner SL, Thompson CB. Structural analysis of CTLA-4 function in vivo. J Immunol 2000;164:5319-5327.
113. Marengere LE, Waterhouse P, Duncan GS, Mittrucker HW, Feng GS, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996;272:1170-1173.
114. 2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70. J Exp Med 1997;186:1645-1653.
115. Guntermann C, Alexander DR. CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. J Immunol 2002;168:4420-4429.
116. Olsson C, Riesbeck K, Dohlsten M, Michaelsson E, Riebeck K. CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts. J Biol Chem 1999;274:14400-14405.
117. Fraser JH, Rincon M, McCoy KD, Le Gros G. CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells. Eur J Immunol 1999;29:838-844.
118. Schneider H, Prasad KV, Shoelson SE, Rudd CE. CTLA-4 binding to the lipid kinase phosphatidylinositol 3-kinase in T cells. J Exp Med 1995;181:351-355.
119. Tolias KF, Cantley LC. Pathways for phosphoinositide synthesis. Chem Phys Lipids 1999;98:69-77.
120. Nishibe S, Wahl MI, Hernandez-Sotomayor SM, Tonks NK, Rhee SG, Carpenter G. Increase of the catalytic activity of phosphohpase C-gamma 1 by tyrosine phosphorylation. Science 1990;250:1253-1256.
121. Park DJ, Rho HW, Rhee SG. CD3 stimulation causes phosphorytation of phospholipase C-gamma 1 on serine and tyrosine residues in a human T-cell line. Proc Natl Acad Sci USA 1991;88:5453-5456.
122. Sasaki T, Hasegawa-Sasaki H. Activation of polyphosphoinositide phospholipase C by guanosine 5′-O-(3-thio)triphosphate and fluoroaluminate in membranes prepared from a human T cell leukemia line, JURKAT. FEBS Lett 1987;218:87-92.
123. June CH, Fletcher MC, Ledbetter JA, Samelson LE. Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. J Immunol 1990;144:1591-1599.
124. Sun Z et al. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature 2000;404:402-407.
125. Arendt CW, Albrecht B, Soos TJ, Littman DR. Protein kinase C-theta: signaling from the center of the T-cell synapse. Curr Opin Immunol 2002;14:323-330.
126. Truneh A, Albert F, Golstein P, Schmitt-Verhulst AM. Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 1985;313:318-320.
127. Berney SM, Atkinson TP. Phosphatidylinositol hydrolysis in freshly isolated human T lymphocytes. J Immunol Methods 1995;186:71-77.
128. Zaru R, Berrie CP, Iurisci C, Corda D, Valitutti S. CD28 co-stimulates TCR/CD3-induced phosphoinositide turnover in human T lymphocytes. Eur J Immunol 2001;31:2438-2447.
129. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998;8:89-95.
130. Sloan-Lancaster J, Steinberg TH, Allen PM. Selective activation of the calcium signaling pathway by altered peptide ligands. J Exp Med 1996;184:1525-1530.
131. Macian F, Garcia-Cozar F, Im SH, Horton HF, Byrne MC, Rao A. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002;109:719-731.
132. Prud'homme GJ, Vanier LE, Bocarro DC, Ste-Croix H. Effects of cyclosporin A, rapamycin, and FK520 on peripheral T-cell deletion and anergy. Cell Immunol 1995;164:47-56.
133. Schwartz RH, Mueller DL, Jenkins MK, Quill H. T-cell clonal anergy. Cold Spring Harbor Symp Quant Biol 1989;54 (Part 2):605-610.
134. Lyakh L, Ghosh P, Rice NR. Expression of NFAT-family proteins in normal human T cells. Mol Cell Biol 1997;17:2475-2484.
135. Xanthoudakis S, et al. An enhanced immune response in mice lacking the transcription factor NFAT1. Science 1996;272:892-895.
136. Hodge MR, Ranger AM, Charles de la Brousse F, Hoey T, Grusby MJ, Glimcher LH. Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice. Immunity 1996;4:397-405.
137. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-1657.
138. Hong Z, Verma DP. A phosphatidylinositol 3-kinase is induced during soybean nodule organogenesis and is associated with membrane proliferation. Proc Natl Acad Sci USA 1994;91:9617-9621.
139. Otsu M, et al. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middie-T/pp60c-src complexes, and PI3-kinase. Cell 1991;65:91-104.
140. Hu P, Mondmo A, Skolnik EY, Schlessinger J. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. Mol Cell Biol 1993;13:7677-7688.
141. Inukai K, et al. A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase structurally similar to p55PIK is generated by alternative splicing of the p85alpha gene. J Biol Chem 1996;271:5317-5320.
142. Pons S, et al. The structure and function of p55PIK reveal a new regulatory subunit for phosphatidylinositol 3-kinase. Mol Cell Biol 1995;15:4453-4465.
143. Fantl WJ, et al. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 1992;69:413-423.
144. Varticovski L, Daley GQ, Jackson P, Baltimore D, Cantley LC. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol 1991;11:1107-1113.
145. Whitman M, Downes CP, Keeler M, Keller T, Candey L. Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature 1988;332:644-646.
146. Alessi DR, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997;7:261-269.
147. Stokoe D, et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997;277:567-570.
148. Ward SG, Wilson A, Turner L, Westwick J, Sansom DM. Inhibition of CD28-mediated T cell costimulation by the phosphoinositide 3-kinase inhibitor wortmannin. Eur J Immunol 1995;25:526-532.
149. Eder AM, Dominguez L, Franke TF, Ashwell JD. Phosphoinositide 3-kinase regulation of T cell receptor-mediated interleukin-2 gene expression in normal T cells. J Biol Chem 1998;273:28025-28031.
150. kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J Immunol 2002;168:2729-2736.
151. Cai YC, Cefai D, Schneider H, Raab M, Nabavi N, Rudd CE. Selective CD28pYMNM mutations implicate phosphatidylinositol 3-kinase in CD86-CD28-mediated costimulation. Immunity 1995;3:417-426.
152. Exley M, Varticovski L, Peter M, Sancho J, Terhorst C. Association of phosphatidylinositol 3-kinase with a specific sequence of the T cell receptor zeta chain is dependent on T cell activation. J Biol Chem 1994;269:15140-15146.
153. Carrera A, Rodriguez-Borlado I., Martinez-Alonso C, Merida I. T cell receptor-associated alpha-phosphatidylinositol 3-kinase becomes activated by T cell receptor cross-linking and requires pp56lck. J Biol Chem 1994;269:19435-19440.
154. de Aos I, et al. Tyrosine phosphorylation of the CD3-epsilon subunit of the T cell antigen receptor mediates enhanced association with phosphatidylinositol 3-kinase in Jurkat T cells. J Biol Chem 1997;272:25310-25318.
155. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995;378:785-789.
156. Stambolic V, Ruel L, Woodgett JR, Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996;6:1664-1668.
157. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998;273:13150-13156.
158. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996;93:8455-8459.
159. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science 1997;275:1930-1934.
160. Shan X, et al. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation. Mol Cell Biol 2000;20:6945-6957.
161. Astoul E, Cantrell DA, Edmunds C, Ward SG. PI 3-K and T-cell activation: limitations of T-leukemic cell lines as signaling models. Trends Immunol 2001;22:490-496.
162. Chantry D, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997;272:19236-19241.
163. Vanhaesebroeck B, et al. P110delta, a novel phosphomositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997;94:4330-4335.
164. Okkenhaug K, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297:1031-1034.
165. Taub DD, et al. Induction of alloantigen-specific T cell tolerance through the treatment of human T lymphocytes with wortmannin. J Immunol 1997;158:2745-2755.
166. Stoyanov B, et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 1995;269:690-693.
167. Stephens LR, et al. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p 101. Cell 1997;89:105-114.
168. Sasaki T, et al. Function of PI3K in thymocyte development, T cell activation, and neutrophil migration. Science 2000;287:1040-1046.
169. Harada Y, et al. Critical requirement for the membrane-proximal cytosolic tyrosine residue for CD28-mediated costimulation in vivo. J Immunol 2001;166:3797-3803.
170. Okkenhaug K, et al. A point mutation in CD28 distinguishes proliferative signals from survival signals. Nat Immunol 2001;2:325-332.
171. Kitayama H, Sugimoto Y, Matsuzaki T, Ikawa Y, Noda M. A ras-related gene with transformation suppressor activity. Cell 1989;56:77-84.
172. Cook SJ, Rubinfeld B, Albert I, McCormick F. RapV12 antagonizes Ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts. EMBO J 1993;12:3475-3485.
173. Carey KD, et al. CD28 and the tyrosine kinase lck stimulate mitogen-activated protein kinase activity in T cells via inhibition of the small G protein Rapl. Mol Cell Biol 2000;20:8409-8419.
174. Boussiotis VA, Freeman GJ, Berezovskaya A, Barber DL, Nadler LM. Maintenance of human T cell anergy, blocking of IL-2 gene transcription by activated Rap1. Science 1997;278:124-128.
175. Katagiri K, Hattori M, Minato N, Kinashi T. Rap1 functions as a key regulator of T-cell and antigen-presenting cell interactions and modulates T-cell responses. Mol Cell Biol 2002;22:1001-1015.
176. Reedquist KA, Bos JL. Costimulation through CD28 suppresses T cell receptor-dependent activation of the Ras-like small GTPase Rap1 in human T lymphocytes. J Biol Chem 1998;273:4944-4949.
177. Zwartkruis FJ, Wolthuis RM, Nabben NM, Franke B, Bos JL. Extracellular signal-regulated activation of Rap1 fails to interfere in Ras effector signalling. EMBO J 1998;17:5905-5912.
178. Downward J, Graves JD, Warne PH, Rayter S, Cantrell DA. Stimulation of p2 Iras upon T-cell activation. Nature 1990;346:719-723.
179. Wittinghofer A. Signal transduction via Ras. Biol Chem 1998;379:933-937.
180. Ebinu JO, Bottorff DA, Chan EY, Stang SL, Dunn RJ, Stone JC. RasGRP, a Ras guanyl nucleotide-releasing protein with calcium-and diacylglycerol-binding motifs. Science 1998;280:1082-1086.
181. Yamashita S, et al. CalDAG-GEFIII activation of Ras, R-ras, and Rap1. J Biol Chem 2000;275:25488-25493.
182. Sieh M, Batzer A, Schlessinger J, Weiss A. GRB2 and phosphohpase C-gamma 1 associate with a 36- to 38-kilodalton phosphotyrosine protein after T-cell receptor stimulation. Mol Cell Biol 1994;14:4435-4442.
183. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF. Activation of Raf as a result of recruitment to the plasma membrane. Science 1994;264:1463-1467.
184. Leevers SJ, Paterson HF, Marshall CJ. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 1994;369:411-414.
185. de Vries-Smits AM, Burgering BM, Leevers SJ, Marshall CJ, Bos JL. Involvement of p21ras in activation of extracellular signal-regulated kinase 2. Nature 1992;357:602-604.
186. Marshall CJ. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994;4:82-89.
187. Li W, Whaley CD, Mondino A, Mueller DL. Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T cells. Science 1996;271:1272-1276.
188. Fields PE, Gajewski TF, Fitch FW. Blocked Ras activation in anergic CD4+ T cells. Science 1996;271:1276-1278.
189. DeSilva DR, et al. Inhibition of mitogen-activated protein kinase kinase blocks T cell proliferation but does not induce or prevent anergy. J Immunol 1998;160:4175-4181.
190. Gotoh T, et al. Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol 1995;15:6746-6753.
191. de Rooij J, et al. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 1998;396:474-477.
192. Kawasaki H, et al. A family of cAMP-binding proteins that directly activate Rap1. Science 1998;282:2275-2279.
193. Kawasaki H, et al. A Rap guanine nucleotide exchange factor enriched highly in the basal ganglia. Proc Natl Acad Sci USA 1998;95:13278-13283.
194. Jin TG, et al. Role of the CDC25 homology domain of phospholipase Cepsilon in amplification of Rap1-dependent signaling. J Biol Chem 2001;276:30301-30307.
195. Suga K, et al. CD98 induces LFA-1-mediated cell adhesion in lymphoid cells via activation of Rap1. FEBS Lett 2001;489:249-253.
196. Nassar N, Horn G, Herrmann C, Schere A, McCormick F, Wittinghofer A. The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature 1995;375:554-560.
197. Grader-Beck T, van Puijenboek A, Nadler LM, Boussiotis VB. cAMP inhibits both Ras and Rap1 actiation in primary T cells but only Ras inhibition correlates wit blockade of cell cycle progression. Blood in press.
198. Schmitt JM, Stork PJ. Cyclic AMP-mediated inhibition of cell growth requires the small G protein Rap1. Mol Cell Biol 2001;21:3671-3683.
199. Jenkins MK. The role of cell division in the induction of clonal allergy. Immunol Today 1992;13:69-73.
200. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999;162:2775-2784.
201. Schorle H, Holtschke T, Hunig T, Schimpl A, Horak I. Development and function oft cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991;352:621-624.
202. Boonen GJ, van Dijk AM, Verdonck LF, van Lier RA, Rijksen G, Medema RH. CD28 induces cell cycle progression by IL-2-independent down-regulation of p27kip1 expression in human peripheral T lymphocytes. Eur J Immunol 1999;29:789-798.
203. Appleman LJ, Berezovskaya A, Grass I, Boussiotis VA. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression. J Immunol 2000;164:144-151.
204. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-1512.
205. Polyak K, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
206. kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia and pituitary tumors. Cell 1996;85:707-720.
207. kip1. Nature 2000;404:782-787.
208. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM. Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 1999;398:630-634.
209. Brunet A, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-868.
210. Halevy O, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995;267:1018-1021.
211. Pagano M, et al. Role of the ubiquitin-proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
212. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-199.
213. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27 (Kip1) ubiquitination and degradation is regulated by the SCF(Skp2) complex through phosphorylated Thr187 in p27. Curr Biol 1999;9:661-664.
214. Ganoth D, et al. The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27. Nat Cell Biol 2001;3:321-324.
215. Spruck C, et al. A CDK-independent function of mammalian Cks1. Targeting of SCF(Skp2) to the CDK inhibitor p27(Kip1). Mol Cell 2001;7:639-650.
216. Kip1, polyploidy and centrosome overduplication. EMBO J 2000;19:2069-2081.
217. Latres E, et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci USA 2001;98:2515-2520.
218. Tuosto L, Acuto O. CD28 affects the earliest signaling events generated by TCR engagement. Eur J Immunol 1998;28:2131-2142.
219. Cai Z, Kishimoto H, Brunmark A, Jackson MR, Peterson PA, Sprent J. Requirements for peptide-induced T cell receptor downregulation on naive CDS+ T cells. J Exp Med 1997;185:641-651.
220. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999;283:680-682.
221. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. Three-dimensional segregation of supramolecular activation dusters in T cells. Nature 1998;395:82-86.